NASDAQ:IRWD

Ironwood Pharmaceuticals Stock Insider Trading

Healthcare > Drug Manufacturers - Specialty & Generic

Buy IRWD

*Your capital is at risk

$3.24

-0.0400 (-1.22%)

At Close: Jun 03, 2026

Ironwood Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -92.83. In total, the insiders bought 4.54M and sold 7.68M IRWD shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-92.83
● Buy	4.54M shares
● Sell	7.68M shares
58% Buy Activity Moderate Negative Correlation
Sell Signal High Confidence Mar 17, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -92.83. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 10, 2025 Sell	Class A Common Stock S-Sale	Silver Ronald Principal Accounting Officer	Officer	12 048 Value: $21.2K
Feb 10, 2025 Sell	Class A Common Stock S-Sale	Mccourt Thomas A Chief Executive Officer	CEO / President	139 064 Value: $244.8K
Jan 27, 2025 Buy	Class A Common Stock A-Award	Silver Ronald Principal Accounting Officer	Officer	133 333 Value: $506.7K
Jan 27, 2025 Buy	Class A Common Stock A-Award	Martini Gregory S. Chief Financial Officer	C-Suite Officer	111 111 Value: $422.2K
Jan 27, 2025 Buy	Class A Common Stock	Martini Gregory S. Chief Financial Officer	C-Suite Officer	0 Value: $0
Jan 27, 2025 Buy	Employee Stock Options (Right to Buy)	Martini Gregory S. Chief Financial Officer	C-Suite Officer	3 307 Value: $55.9K
Jan 27, 2025 Buy	Employee Stock Options (Right to Buy)	Martini Gregory S. Chief Financial Officer	C-Suite Officer	1 587 Value: $20.6K
Jan 27, 2025 Buy	Employee Stock Options (Right to Buy)	Martini Gregory S. Chief Financial Officer	C-Suite Officer	1 587 Value: $20.6K
Jan 27, 2025 Buy	Employee Stock Options (Right to Buy)	Martini Gregory S. Chief Financial Officer	C-Suite Officer	3 307 Value: $55.9K
Jan 27, 2025 Buy	Class A Common Stock	Martini Gregory S. Chief Financial Officer	C-Suite Officer	0 Value: $0
Jan 27, 2025 Buy	Class A Common Stock A-Award	Martini Gregory S. Chief Financial Officer	C-Suite Officer	111 111 Value: $422.2K
Jan 27, 2025 Buy	Class A Common Stock A-Award	Silver Ronald Principal Accounting Officer	Officer	133 333 Value: $506.7K
Jan 17, 2025 Buy	Class A Common Stock A-Award	Shetzline Michael SVP, Cmo, Head-res&drug	Officer	48 224 Value: $176.5K
Jan 17, 2025 Buy	Class A Common Stock A-Award	John Minardo Chief Legal Officer	Officer	40 187 Value: $147.1K
Jan 17, 2025 Buy	Class A Common Stock A-Award	Mccourt Thomas A Chief Executive Officer	CEO / President	147 354 Value: $539.3K
Jan 17, 2025 Buy	Class A Common Stock A-Award	Mccourt Thomas A Chief Executive Officer	CEO / President	147 354 Value: $539.3K
Jan 17, 2025 Buy	Class A Common Stock A-Award	John Minardo Chief Legal Officer	Officer	40 187 Value: $147.1K
Jan 17, 2025 Buy	Class A Common Stock A-Award	Shetzline Michael SVP, Cmo, Head-res&drug	Officer	48 224 Value: $176.5K
Dec 16, 2024 Buy	Class A Common Stock A-Award	Denner Alexander J	Director	4 249 Value: $14.7K
Dec 16, 2024 Buy	Class A Common Stock A-Award	Denner Alexander J	Director	4 249 Value: $14.7K
Nov 18, 2024 Sell	Class A Common Stock S-Sale	Davis Andrew SVP, Chief Business Officer	Officer	5 360 Value: $21.9K
Nov 18, 2024 Sell	Class A Common Stock S-Sale	Emany Sravan Kumar SVP, COO And CFO	C-Suite Officer	11 001 Value: $44.9K
Nov 18, 2024 Sell	Class A Common Stock S-Sale	Emany Sravan Kumar SVP, COO And CFO	C-Suite Officer	11 001 Value: $44.9K
Nov 18, 2024 Sell	Class A Common Stock S-Sale	Davis Andrew SVP, Chief Business Officer	Officer	5 360 Value: $21.9K
Sep 16, 2024 Buy	Class A Common Stock A-Award	Denner Alexander J	Director	3 282 Value: $14.7K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT IRONWOOD PHARMACEUTICALS

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European...

Read Full Profile Here